- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 868251, 7 pages
Autoantibodies to Apolipoprotein A-1 in Cardiovascular Diseases: Current Perspectives
1Translational Research Sciences, F.n Hoffman-La Roche Ltd., 4070 Basel, Switzerland
2Department of Human Protein Science, Geneva Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland
3Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospital Geneva, 1211 Geneva, Switzerland
4Laboratory Medicine Service, Department of Genetics and Laboratory Medicine, Geneva University Hospital, 4 Rue Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland
Received 2 October 2012; Accepted 19 October 2012
Academic Editor: Dimitrios P. Bogdanos
Copyright © 2012 P. C. Teixeira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- R. R. S. Packard and P. Libby, “Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction,” Clinical Chemistry, vol. 54, no. 1, pp. 24–38, 2008.
- C. Blasi, “The autoimmune origin of atherosclerosis,” Atherosclerosis, vol. 201, no. 17, p. 32, 2008.
- B. J. Skaggs, B. H. Hahn, and M. McMahon, “Accelerated atherosclerosis in patients with SLE—mechanisms and management,” Nature Reviews Rheumatology, vol. 8, no. 4, pp. 214–223, 2012.
- C. B. Zeller and S. Appenzeller, “Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors,” Current Cardiology Reviews, vol. 4, no. 2, pp. 116–122, 2008.
- M. J. Kaplan, “Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment,” Rheumatic Disease Clinics of North America, vol. 36, no. 2, pp. 405–426, 2010.
- P. Roux-Lombard, S. Pagano, F. Montecucco, N. Satta, and N. Vuilleumier, “Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases,” Clinical Reviews in Allergy and Immunology, pp. 1–14, 2010.
- K. A. Rye, C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter, “The metabolism and anti-atherogenic properties of HDL,” Journal of lipid research, vol. 50, pp. S195–S200, 2009.
- S. M. Gordon, S. Hofmann, D. S. Askew, and W. S. Davidson, “High density lipoprotein: it's not just about lipid transport anymore,” Trends in Endocrinology and Metabolism, vol. 22, no. 1, pp. 9–15, 2011.
- C. Besler, T. F. Lüscher, and U. Landmesser, “Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease,” EMBO Molecular Medicine, vol. 4, no. 4, pp. 251–268, 2012.
- A. R. Dinu, J. T. Merrill, C. Shen, I. V. Antonov, B. L. Myones, and R. G. Lahita, “Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE,” Lupus, vol. 7, no. 5, pp. 355–360, 1998.
- H. Abe, N. Tsuboi, S. Suzuki et al., “Anti-apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosusr,” Journal of Rheumatology, vol. 28, no. 5, pp. 990–995, 2001.
- J. Delgado Alves, S. Kumar, and D. A. Isenberg, “Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome,” Rheumatology, vol. 42, no. 7, pp. 893–899, 2003.
- J. Delgado Alves, P. R. J. Ames, S. Donohue et al., “Antibodies to high-density lipoprotein and β2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome,” Arthritis and Rheumatism, vol. 46, no. 10, pp. 2686–2694, 2002.
- J. R. Batuca, P. R. J. Ames, D. A. Isenberg, and J. Delgado Alves, “Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus,” Annals of the New York Academy of Sciences, vol. 1108, pp. 137–146, 2007.
- P. R. J. Ames, E. Matsuura, J. R. Batuca et al., “High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome,” Lupus, vol. 19, no. 6, pp. 711–716, 2010.
- B. J. Van Lenten, S. Y. Hama, F. C. De Beer et al., “Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures,” Journal of Clinical Investigation, vol. 96, no. 6, pp. 2758–2767, 1995.
- N. Vuilleumier, S. Bas, S. Pagano et al., “Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2640–2650, 2010.
- I. M. Loftus, A. R. Naylor, S. Goodall et al., “Increased matrix metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption,” Stroke, vol. 31, no. 1, pp. 40–47, 2000.
- M. Anselmi, U. Garbin, P. Agostoni et al., “Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques,” Atherosclerosis, vol. 185, no. 1, pp. 114–120, 2006.
- N. Vuilleumier, J. Bratt, R. Alizadeh, T. Jogestrand, I. Hafström, and J. Frostegård, “Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity,” Scandinavian Journal of Rheumatology, vol. 39, no. 6, pp. 447–453, 2010.
- A. Finckh, D. S. Courvoisier, S. Pagano et al., “Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores ?” Arthritis Care & Research, vol. 64, no. 6, pp. 817–825, 2012.
- N. Vuilleumier, G. Reber, R. James et al., “Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease,” Journal of Autoimmunity, vol. 23, no. 4, pp. 353–360, 2004.
- S. Urieli-Shoval, R. P. Linke, and Y. Matzner, “Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states,” Current Opinion in Hematology, vol. 7, no. 1, pp. 64–69, 2000.
- E. Malle, A. Steinmetz, and J. G. Raynes, “Serum amyloid A (SAA): an acute phase protein and apolipoprotein,” Atherosclerosis, vol. 102, no. 2, pp. 131–146, 1993.
- N. Vuilleumier, E. Charbonney, L. Fontao et al., “Anti-(apolipoprotein A-I) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome,” Clinical Science, vol. 115, no. 1-2, pp. 25–33, 2008.
- N. Vuilleumier, M. F. Rossier, S. Pagano et al., “Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction,” European Heart Journal, vol. 31, no. 7, pp. 815–823, 2010.
- K. Fox, I. Ford, P. G. Steg, M. Tendera, M. Robertson, and R. Ferrari, “Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial,” The Lancet, vol. 372, no. 9641, pp. 817–821, 2008.
- W. B. Kannel, C. Kannel, R. S. Paffenbarger, and A. Cupples, “Heart rate and cardiovascular mortality: the Framingham study,” American Heart Journal, vol. 113, no. 6, pp. 1489–1494, 1987.
- A. Diaz, M. G. Bourassa, M. C. Guertin, and J. C. Tardif, “Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease,” European Heart Journal, vol. 26, no. 10, pp. 967–974, 2005.
- S. Pagano, N. Satta, D. Werling et al., “Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex,” Journal of Internal Medicine, vol. 272, no. 4, pp. 344–357, 2012.
- N. Vuilleumier, S. Pagano, K. Lalhou et al., “Head-to-head comparison of auto-antibodies for cardiovascular outcome prediction after myocardial infarction: a prospective study,” Journal of Clinical and Experimental Cardiology. In press.
- T. P. Murphy, R. Dhangana, M. J. Pencina, A. M. Zafar, and R. B. D'Agostino, “Performance of current guidelines for coronary heart disease prevention: optimal use of the Framingham-based risk assessment,” Atherosclerosis, vol. 216, no. 2, pp. 452–457, 2011.
- P. F. Keller, S. Pagano, P. Roux-Lombard et al., “Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction,” Journal of Internal Medicine, vol. 271, no. 5, pp. 451–462, 2012.
- T. Reichlin, W. Hochholzer, S. Bassetti et al., “Early diagnosis of myocardial infarction with sensitive cardiac troponin assays,” New England Journal of Medicine, vol. 361, no. 9, pp. 858–867, 2009.
- F. Montecucco, N. Vuilleumier, S. Pagano et al., “Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability,” European Heart Journal, vol. 32, no. 4, pp. 412–421, 2011.
- S. M. Schwartz, Z. S. Galis, M. E. Rosenfeld, and E. Falk, “Plaque rupture in humans and mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 4, pp. 705–713, 2007.
- P. Libby, “Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis.,” Journal of Lipid Research, vol. 50, pp. S352–357, 2009.
- M. J. Sarnak, A. S. Levey, A. C. Schoolwerth et al., “Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention,” Hypertension, vol. 42, no. 5, pp. 1050–1065, 2003.
- P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimbürger, and Z. Massy, “Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?” Clinical Journal of the American Society of Nephrology, vol. 3, no. 2, pp. 505–521, 2008.
- A. B. Hauser, A. E. M. Stinghen, S. Kato et al., “Characteristics and causes of immune dysfunction related to uremia and dialysis,” Peritoneal Dialysis International, vol. 28, supplement 3, pp. S183–S187, 2008.
- J. J. Carrero, X. Hua, P. Stenvinkel et al., “Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis,” Nephrology Dialysis Transplantation, vol. 24, no. 11, pp. 3454–3460, 2009.
- K. Pawlak, D. Pawlak, and M. Mysliwiec, “Oxidative stress influences CC-chemokine levels in hemodialyzed patients,” Nephron Physiology, vol. 96, no. 4, pp. p105–p112, 2004.
- M. Pruijm, J. Schmidtko, A. Aho et al., “High prevalence of anti-Apolipoprotein A-1 autoantibodies in maintenance haemodialysis and associations with dialysis vintage,” Therapeutic Apheresis and Dialysis. In press.
- T. Ohtake, K. Ishioka, K. Honda et al., “Impact of coronary artery calcification in hemodialysis patients: risk factors and associations with prognosis,” Hemodialysis International, vol. 14, no. 2, pp. 218–225, 2010.
- N. D. Vaziri, M. Navab, and A. M. Fogelman, “HDL metabolism and activity in chronic kidney disease,” Nature Reviews Nephrology, vol. 6, no. 5, pp. 287–296, 2010.
- N. Satta, S. Dunoyer-Geindre, G. Reber et al., “The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies,” Blood, vol. 109, no. 4, pp. 1507–1514, 2007.
- N. Satta, E. K. O. Kruithof, C. Fickentscher et al., “Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies,” Blood, vol. 117, no. 20, pp. 5523–5531, 2011.
- S. I. Yokota, S. Minota, and N. Fujii, “Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors,” International Immunology, vol. 18, no. 4, pp. 573–580, 2006.
- M. F. Rossier, S. Pagano, M. Python et al., “Antiapolipoprotein A-1 IgG chronotropic effects require nongenomic action of aldosterone on L-type calcium channels,” General Endocrinology, vol. 153, no. 3, pp. 1269–1278, 2012.
- R. Srivastava, S. Yu, B. W. Parks, L. L. Black, and J. H. Kabarowski, “Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice,” Arthritis and Rheumatism, vol. 63, no. 1, pp. 201–211, 2011.
- U. N. Khot, M. B. Khot, C. T. Bajzer et al., “Prevalence of conventional risk factors in patients with coronary heart disease,” Journal of the American Medical Association, vol. 290, no. 7, pp. 898–904, 2003.
- U. Nussinovitch and Y. Shoenfeld, “Intravenous immunoglobulin-indications and mechanisms in cardiovascular diseases,” Autoimmunity Reviews, vol. 7, no. 6, pp. 445–452, 2008.